Skip to main content

Moderna’s stock slides as earnings fall short of estimates amid steep decline in COVID-vaccine sales

With the boost Moderna got from COVID vaccines now fading, analysts are focused on the company's pipeline.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.